🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Development of a Synovium-on-a-Chip Microphysiological System to Interrogate Pathobiology and Enhance Precision Medicine in Rheumatoid Arthritis
Organization NEW YORK UNIVERSITYLocation NEW YORK, UNITED STATESPosted 1 Mar 2024Deadline 28 Feb 2026 ⚠️
NIHUS FederalResearch GrantFY2025(TNF)-α3-10CAMCF-IAffectAtrophic ArthritisB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Stimulatory Factor-2B7-1BB1BCDFBSF-2BSF2Beta Proprotein Interleukin 1Biologic ModelsBiological MimeticsBiological ModelsBiomedical EngineeringBiomimeticsBiophysicsBiopsyBiopsy SampleBiopsy SpecimenBloodBlood CirculationBlood Reticuloendothelial SystemBlood VesselsBlood monocyteBloodstreamBody TissuesCD28LGCD28LG1CD80CD80 geneCXCL8CachectinCell BodyCell Communication and SignalingCell Growth in NumberCell MultiplicationCell ProliferationCell SignalingCellsCellular ProliferationCharacteristicsChronicClinicalCuesDataDevelopmentDevicesDisease remissionEconomic BurdenEndogenous Interferon BetaEndothelial CellsEngineeringFibroblast InterferonFibroblastsGCP1GM-CSFGasesGene ExpressionGoalsGranulocyte-Macrophage Colony-Stimulating FactorHPGFHepatocyte-Stimulating FactorHeterogeneityHistamine-Producing Cell-Stimulating FactorHumanHybridoma Growth FactorHypoxiaHypoxicIFN-beta 2IFN-βIFNB2IFNbIL-1 betaIL-1 βIL-1-bIL-1βIL-6IL-8IL1-BetaIL1-βIL1B ProteinIL1F2IL1βIL6 ProteinIL8IL8 geneIMiDImmuneImmune Modulation TherapyImmune infiltratesImmune mediated therapyImmune modulatory therapeuticImmune responseImmunesImmunocompetentImmunologically Directed TherapyImmunotherapyIn VitroIndividualInflammationInflammatoryInterferon Type IInterferon-βInterleukin 1betaInterleukin-1 betaInterleukin-1βInterleukin-6Intracellular Communication and SignalingJoint DiseasesJointsK60LAB7MGI-2MMPsMacrophageMacrophage-Derived TNFMarrow monocyteMatrix MetalloproteinasesMeasurementMeasuresMembrana Synovialis Capsulae ArticularisMethodologyMicroanatomyMicrofluidicsMicroscopic AnatomyModel SystemModelingModern ManMolgramostinMonocyte-Derived TNFMorbidityMorbidity - disease rateMyeloid Differentiation-Inducing ProteinMφNatural Interferon BetaNatural human interferon betaOutcomeOutcome MeasureOxygen DeficiencyPathogenesisPathogenicityPathologic ProcessesPathological ProcessesPatientsPerfusionPeripheralPhysiologicPhysiologicalPhysiologyPlasmacytoma Growth FactorPopulationPreinterleukin 1 BetaProductionProteomicsRNA SeqRNA sequencingRNAseqRemissionResearchResistanceRheumatoid ArthritisRoleSCYB8Sampling StudiesSelection for TreatmentsSignal TransductionSignal Transduction SystemsSignalingStructureSynovial CellSynovial MembraneSynoviumSystemTC-GM-CSFTNFTNF ATNF AlphaTNF geneTNF-αTNFATNFαTSG-1TestingTherapeutic AgentsTissuesTreatment outcomeTumor Necrosis FactorTumor Necrosis Factor-alphaTumor-Cell Human GM Colony-Stimulating FactorVascular SystemVascularizationWorkarthropathicarthropathiesarthropathyb-ENAPbio-engineeredbio-engineersbioengineeringbiological engineeringbiological heterogeneitybiological signal transductionbiomarker identificationbiophysical foundationbiophysical principlesbiophysical sciencescell typechip modelchip systemclinical trial on a chipclinical trial on chipcytokinedensitydevelopmentaldisease modeldisorder modeleffective therapyeffective treatmenthost responseidentification of biomarkersidentification of new biomarkersimmune cell infiltrateimmune competentimmune microenvironmentimmune modulating agentsimmune modulating drugimmune modulating therapeuticsimmune modulatory agentsimmune modulatory drugsimmune modulatory therapiesimmune modulatory treatmentimmune regulation therapyimmune regulation treatmentimmune regulatory therapyimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmune-modulation treatmentimmuno therapyimmunomodulating agentsimmunomodulating drugsimmunomodulation therapyimmunomodulation treatmentimmunomodulator agentimmunomodulator drugimmunomodulator medicationimmunomodulator prodrugimmunomodulator therapeuticimmunomodulator therapiesimmunomodulator treatmentimmunomodulator-based therapiesimmunomodulatory agentsimmunomodulatory biologicsimmunomodulatory drugsimmunomodulatory therapeuticsimmunomodulatory therapiesimmunomodulatory treatmentimmunoregulatory therapyimmunoregulatory treatmentimmunoresponseimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentin vivoineffective therapiesineffective treatmentinflammatory environmentinflammatory milieuinsightinterferon beta 2joint disorderloss of functionmarker identificationmeasurable outcomemicrophysiologic modelmicrophysiologic platformmicrophysiologic systemmicrophysiology modelmicrophysiology platformmicrophysiology systemmonocytemortalitynovelon a chipon chiporgan chiporgan on a chiporgan on chipoutcome measurementpatient stratificationpersonalization of treatmentpersonalized medicinepersonalized therapypersonalized treatmentprecision medicineprecision-based medicinepressurepreventpreventingproteomic signaturereal-time imagesrealtime imagerecruitresistance to therapyresistantresistant to therapyresponse to therapyresponse to treatmentrheumatic arthritisscreeningscreeningsselection of treatmentsocial rolestratified patientsynergismtherapeutic immunomodulationtherapeutic immunoregulationtherapeutic resistancetherapeutic responsetherapy resistanttherapy responsetherapy selectiontranscriptome sequencingtranscriptomic sequencingtranscriptomicstreatment resistancetreatment responsetreatment responsivenesstreatment selectiontumor immune microenvironmenttumor-immune system interactionsvascularµfluidic
Applications closed.
Description preview
PROJECT SUMMARY
Rheumatoid arthritis (RA) is the most common inflammatory joint disease caused by a chronic inflammation in
joints, where no effective treatment is currently available. Currently there is no effective model can accurately
dissect RA pathogenesis and consistently predict the effect of a therapeutic agent in patients. Better model…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click